protein

LRRK2 Mutant (I2020T), Active

MBS515533

0.005 mg

340 USD

Recombinant Protein

LRRK2 Mutant (I2020T), Active

[LRRK2]

[Homo sapiens leucine rich repeat kinase 2 (LRRK2), mRNA; Leucine-rich repeat serine/threonine-protein kinase 2; leucine-rich repeat serine/threonine-protein kinase 2; leucine rich repeat kinase 2; Dardarin]

[LRRK2]

[PARK8; RIPK7; ROCO2; AURA17; DARDARIN]

[LRRK2; LRRK2; PARK8; RIPK7; ROCO2; AURA17; DARDARIN; PARK8]

Sf9 cells

>70%

Recombinant protein stored in 50mM Tris-HCl, pH 7.5, 150mM NaCl, 10mM glutathione, 0.1mM EDTA, 0.25mM DTT, 0.1mM PMSF, 25% glycerol.

0.05 ug/ul

Store product at -70°C. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles.

Specific Activity

Purity

Enzymes; Active Kinase Mutants

Description: Recombinant human LRRK2 (I2020T) (968-end) was expressed by baculovirus in Sf9 insect cells using an N-terminal GST tag. The LRRK2 gene accession number is NM_198578. Scientific Background: LRRK2 or leucine-rich repeat kinase is a protein with an ankryin repeat region, a leucine-rich repeat (LRR) domain, a kinase domain, a DFG-like motif, a RAS domain, a GTPase domain, a MLK-like domain, and a WD40 domain. Mutations in LRRK2 are the most frequent known cause of autosomal dominant and idiopathic Parkinson's disease with prevalent mutations being found within the GTPase and kinase domains (1). LRRK2 cooperates with MET to promote efficient tumor cell growth and survival in various cancers. Down-regulation of LRRK2 in cultured tumor cells compromises MET activation and selectively reduces downstream MET signaling to mTOR and STAT3 (2).

1. Yao C, LRRK2-mediated neurodegeneration and dysfunction of dopaminergic neurons in a Caenorhabditis elegans model of Parkinson's disease. Neurobiol Dis. 2010 Oct;40 (1):73-81. 2. Looyenga BD, Chromosomal amplification of leucine-rich repeat kinase-2 (LRRK2) is required for oncogenic MET signaling in papillary renal and thyroid carcinomas. Proc Natl Acad Sci U S A. 2011 Jan 25;108 (4):1439-44.

171846277

NM_198578.3

NM_198578

Q5S007

Allograft Rejection Pathway (920963); MAPK Signaling Pathway (198779); PTK6 Promotes HIF1A Stabilization Pathway (1383032); Parkinson's Disease Pathway (83098); Parkinsons Disease Pathway (705377); Signal Transduction Pathway (1269379); Signaling By PTK6 Pathway (1383025); Wnt Signaling Pathway And Pluripotency (198847)

This gene is a member of the leucine-rich repeat kinase family and encodes a protein with an ankryin repeat region, a leucine-rich repeat (LRR) domain, a kinase domain, a DFG-like motif, a RAS domain, a GTPase domain, a MLK-like domain, and a WD40 domain. The protein is present largely in the cytoplasm but also associates with the mitochondrial outer membrane. Mutations in this gene have been associated with Parkinson disease-8. [provided by RefSeq, Jul 2008]

LRRK2: a large multidomain protein kinase with a TKL-type kinase domain, multiple protein-protein interaction domains and a mitochondrial Rho domain (MIRO). May play a role in the etiology of Parkinson disease. May also have GTPase activity. Positively regulates autophagy through a calcium-dependent activation of the CaMKK/AMPK signaling pathway. The process involves activation of nicotinic acid adenine dinucleotide phosphate (NAADP) receptors, increase in lysosomal pH, and calcium release from lysosomes. Interacts with PARK2, PRDX3 and TPCN2. Expressed throughout the adult brain, but at a lower level than in heart and liver. Expressed in the cerebellum, cerebral cortex, medulla, spinal cord occipital pole, frontal lobe, temporal lobe and putamen. Expression is particularly high in brain dopaminoceptive areas. Defects in LRRK2 are the cause of Parkinson disease type 8 (PARK8). A slowly progressive neurodegenerative disorder characterized by bradykinesia, rigidity, resting tremor, postural instability, neuronal loss in the substantia nigra, and the presence of neurofibrillary MAPT (tau)-positive and Lewy bodies in some patients. Protein type: EC 2.7.11.1; Kinase, protein; LRRK family; Protein kinase, Ser/Thr (non-receptor); Protein kinase, TKL; TKL group. Chromosomal Location of Human Ortholog: 12q12. Cellular Component: axon; cell soma; cytoplasm; cytoplasmic vesicle; cytosol; dendrite; dendrite cytoplasm; endoplasmic reticulum; endosome; extracellular space; Golgi apparatus; Golgi-associated vesicle; growth cone; inclusion body; intracellular; intracellular membrane-bound organelle; lysosome; microvillus; mitochondrial inner membrane; mitochondrial matrix; mitochondrial membrane; mitochondrial outer membrane; mitochondrion; neuron projection; nucleus; perikaryon; plasma membrane; terminal button. Molecular Function: actin binding; clathrin binding; glycoprotein binding; GTP binding; GTP-dependent protein kinase activity; GTPase activator activity; GTPase activity; identical protein binding; kinase activity; MAP kinase kinase activity; microtubule binding; protein binding; protein homodimerization activity; protein kinase A binding; protein kinase activity; protein serine/threonine kinase activity; receptor signaling complex scaffold activity; Rho GTPase binding; SNARE binding; syntaxin-1 binding; tubulin binding. Biological Process: activation of MAPK activity; activation of MAPKK activity; calcium-mediated signaling; cellular response to starvation; determination of adult life span; endocytosis; Golgi organization and biogenesis; GTP metabolic process; intracellular distribution of mitochondria; lysosome organization and biogenesis; MAPKKK cascade; mitochondrion localization; mitochondrion organization and biogenesis; negative regulation of macroautophagy; negative regulation of protein amino acid phosphorylation; negative regulation of protein binding; neurite morphogenesis; neuromuscular junction development; olfactory bulb development; peptidyl-serine phosphorylation; peptidyl-threonine phosphorylation; phosphorylation; positive regulation of autophagy; positive regulation of dopamine receptor signaling pathway; positive regulation of MAP kinase activity; positive regulation of programmed cell death; positive regulation of proteasomal ubiquitin-dependent protein catabolic process; positive regulation of protein amino acid phosphorylation; positive regulation of protein binding; positive regulation of protein ubiquitination; protein amino acid autophosphorylation; protein amino acid phosphorylation; regulation of autophagy; regulation of dopamine receptor signaling pathway; regulation of excitatory postsynaptic membrane potential; regulation of locomotion; regulation of membrane potential; regulation of mitochondrial depolarization; regulation of neuron maturation; regulation of synaptic transmission, glutamatergic; response to oxidative stress; tangential migration from the subventricular zone to the olfactory bulb; Wnt receptor signaling pathway through beta-catenin. Disease: Parkinson Disease 8, Autosomal Dominant

0.005 mg

340 USD

0.01 mg

460